Tadataka Yamada - 28 Jul 2021 Form 3 Insider Report for Icosavax, Inc. (ICVX)

Role
Director
Signature
/s/ Thomas Russo, Attorney-in Fact
Issuer symbol
ICVX
Transactions as of
28 Jul 2021
Net transactions value
$0
Form type
3
Filing time
28 Jul 2021, 21:23:49 UTC
Previous filing
01 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ICVX Common Stock 124,097 28 Jul 2021 Direct F1
holding ICVX Common Stock 627,229 28 Jul 2021 By Leslie D. Yamada 2016 Trust F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ICVX Stock Option (Right to Buy) 28 Jul 2021 Common Stock 65,748 $1.04 Direct F4
holding ICVX Stock Option (Right to Buy) 28 Jul 2021 Common Stock 481,266 $5.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 64,884 shares subject to repurchase by us, which are subject to vesting.
F2 Includes 53,280 shares subject to repurchase by us, which are subject to vesting.
F3 The securities reported herein may be deemed beneficially owned by Tadataka Yamada, M.D., who is a co-trustees of the Leslie D. Yamada 2016 Trust.
F4 25% of the shares subject to the option will vest on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F5 25% of the shares subject to the option will vest on 3/19/2022, and 1/48th of the shares subject to the option vest monthly thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney